Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493265 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
A Phase 2 study, sponsored by Eisai.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT07493265 is a Phase 2 study that is actively recruiting participants, run by Eisai. The registered enrollment target is 64 participants.
The verdict
NCT07493265, a Phase 2 study, is actively recruiting participants, sponsored by Eisai.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).
Interventions
- DRUG Placebo
- DRUG E2086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07493265
The ClinicalTrials.gov registry entry for NCT07493265 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07493265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07493265 about?
NCT07493265 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy". The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).
What is the current status of trial NCT07493265?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2026-03-26. Estimated completion is 2027-03-01.
What interventions are being tested in trial NCT07493265?
The interventions under investigation include: Placebo (DRUG), E2086 (DRUG).
Who is sponsoring clinical trial NCT07493265?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.